As antibody-drug conjugates become more sophisticated, understanding their behavior requires more than a single analytical perspective. DAR characterization, multi-analyte PK, immunogenicity assessment and intact mass spectrometry are becoming increasingly important for teams working to generate robust development insight from complex ADC candidates.

On 22 April 2026 at 2:00 PM CET, Quinta-Analytica, a Conscio Group company, invites you to join a focused expert webinar organised together with SigutLabs:

ADC Performance by Design: From Linker Chemistry to DAR and Bioanalytical Insight

The session will connect upstream chemistry decisions with downstream analytical and bioanalytical interpretation. Topics will include linker design, conjugation strategy, DAR control, conjugate stability, multi-analyte PK, immunogenicity and high-resolution mass spectrometry for intact ADC analysis.

Program highlights:

  • The Organic Chemist’s Role in Enhancing ADC Performance
    Speaker: Alessandro Panattoni, Head of Chemistry, SigutLabs
  • Navigating the Complexity of ADCs: Integrated Analytical and Bioanalytical Strategies for Next-Generation Biotherapeutics
    Speaker: Milan Maděra, Head of Biologics Department, Conscio Group
  • Opening remarks & ADC market insights
    Host: Jiří Raška, CCO, Conscio Group/Quinta-Analytica

Whether you work in bioanalysis, analytical development, CMC or cross-functional ADC programs, this webinar will offer practical insight into the decisions that influence candidate quality, development readiness and translational understanding. The session includes a live Q&A, giving participants the opportunity to engage directly with the speakers.

Register here to secure your spot. Participation is free.

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.